Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q3 2025
Tonix Pharmaceuticals Holding (TNXP) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $3.3M for the third quarter 2025 (Q3 2025), +17% from a year earlier and +65% from the quarter before.
Tonix Pharmaceuticals Holding, Q3 2025: revenue $3.3M (+17% year over year), net loss $32.0M, operating cash flow −$28.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | +65% | +17% |
| Operating profit | −$33.1M | — | — |
| Net earnings | −$32.0M | — | — |
| Operating cash flow | −$28.8M | — | — |
What changed
Revenue was $3.3M in Q3 2025, up 17% year over year and up 65% from the previous quarter. Zembrace Symtouch was the largest line at 78% of revenue. Tosymra added $371K year over year (up 110%), 79% of the total change.
Operating costs exceeded revenue by $33.1M, an operating margin of -1005.1%. Total costs grew 98% against revenue growth of 17%. The fastest-growing cost line was SG&A (+233%). The quarter ended with a net loss of $32.0M, wider than the previous quarter's $28.3M loss.
Operating cash flow was −$28.8M. Non-cash charges added back $461K of depreciation and amortization and $1.9M of share-based compensation. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$29.7M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the third quarter 2025?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $3.3M for the third quarter 2025 (Q3 2025), +17% from a year earlier and +65% from the quarter before.